RxDoctor Payments Data

Kendra Proctor

Nurse Practitioner · Paris, TXNPI 1396764981

Payments from drug & device makers

$7,739in general payments, 2019–2025

Across 523 payments — averaging $14.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • AbbVie$1K
  • GSK$1K
  • Lilly USA, LLC$816
  • Novo Nordisk$572
  • Pfizer$393
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$7,64599%
  • Education$941%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,739 in reported general payments places this provider in the 95th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$228,439
Medicare patients
376
Services billed
9,657

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide92$85,910
EliquisApixaban57$37,942
FarxigaDapagliflozin Propanediol34$33,553
JardianceEmpagliflozin37$27,654
MounjaroTirzepatide24$24,967
TrulicityDulaglutide23$22,378
XareltoRivaroxaban26$17,088
SymbicortBudesonide/Formoterol Fumarate22$7,383
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$6,385
Spiriva HandihalerTiotropium Bromide11$5,356
Breo ElliptaFluticasone/Vilanterol11$4,306
Levothyroxine Sodium512$3,942
Potassium Chloride130$2,529
Metoprolol Succinate162$2,507
SynthroidLevothyroxine Sodium41$2,314

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$572$85,91092 claims
Lilly USA, LLCMounjaro, Trulicity$816$47,34547 claims
AstraZenecaFarxiga, Symbicort$1,343$40,93756 claims
PfizerEliquis, Paxlovid$393$39,29473 claims
Boehringer IngelheimJardiance$218$27,65437 claims
Johnson & JohnsonXarelto$203$17,08826 claims
GSKAnoro Ellipta, Breo Ellipta$1,023$10,69024 claims
AbbVieSynthroid$1,170$2,31441 claims
Almatica Pharma LLCSertraline Hcl$17$1,146135 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Paris

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →